Rotavirus in New Zealand 2015

Saturday 8th October 2022


A three dose schedule of the oral rotavirus vaccine RotaTeq® was added to the national childhood immunisation schedule on 1 July 2014. This report presents information on rotavirus infections from a variety of sources, including national hospital discharges, sentinel hospital-based surveillance, community and hospital laboratory testing and laboratory genotyping.

Rotavirus hospitalisation rates for children aged under 5 years declined by 85% in 2015 compared with the previous five-year average (2010–2014). In addition, the proportion of all gastroenteritis faecal samples that were positive for rotavirus decreased from a peak of 12–14% pre-vaccine to less than 3% following vaccine introduction.

G12P[8] was the predominant (47.5%) rotavirus genotype detected in 2015. Three rotaviruses, G1P[not typed], G1P[8] and GntP[8] were identified as vaccine-like and were all from partially immunised children. There was a significant decrease in rotavirus infections and in rotavirus as a proportion of all gastroenteritis.

From 1 July 2017, New Zealand will change to the monovalent vaccine Rotarix® with a two-dose schedule. Surveillance of rotavirus infections will be important to monitor trends of severe rotavirus infection and vaccine selection pressure on rotavirus genotypes.

Note: this report has been updated since it was originally published on 22 December 2016.  The only difference is in table 12 where two cases with genotype G12P[8] previously reported as fully immunised have been changed to not immunised.

Note: Click on the document links below to open. These documents are in PDF format. You will need to download the free Adobe Acrobat Reader to view them.


Rotavirus in New Zealand 2015



Rotavirus in New Zealand 2015

Ph: +64 4 914 0700 Fax: +64 4 914 0770 Email: